Literature DB >> 27706906

Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse.

P Larsson1, I Alwis2,3, B Niego2,4, M Sashindranath2,4, P Fogelstrand1, M C L Wu3, L Glise1, M Magnusson1, M Daglas2,4, N Bergh1, S P Jackson2,3, R L Medcalf2,4, S Jern1.   

Abstract

Essentials Stimulating endogenous fibrinolysis could be a novel antithrombotic strategy. The effect of valproic acid on endothelial tissue plasminogen activator in mice was investigated. Valproic acid increased tissue plasminogen activator expression in vascular endothelium. Valproic acid reduced fibrin deposition and thrombus formation after vascular injury.
SUMMARY: Background The endogenous fibrinolytic system has rarely been considered as a target to prevent thrombotic disease. Tissue-type plasminogen activator (t-PA) production is potently increased by histone deacetylase (HDAC) inhibitors in endothelial cells in vitro, but whether this translates into increased vascular t-PA production and an enhanced fibrinolytic capacity in vivo is unknown. Objectives To determine whether the HDAC inhibitor valproic acid (VPA) stimulates production of t-PA in the vasculature of mice, and whether VPA pretreatment affects fibrin deposition and clot formation after mechanical vessel injury. Methods Mice were injected with VPA twice daily for up to 5 days. t-PA mRNA, and antigen expression in the mouse aorta and the circulating levels of t-PA were determined. Fibrin and thrombus dynamics after mechanical vessel injury were monitored with intravital confocal microscopy. Potential effects of VPA on platelets and coagulation were investigated. Results and Conclusions We found that VPA treatment increased vascular t-PA production in vivo and, importantly, that VPA administration was associated with reduced fibrin accumulation and smaller thrombi in response to vascular injury, but still was not associated with an increased risk of bleeding. Furthermore, we observed that higher concentrations of VPA were required to stimulate t-PA production in the brain than in the vasculature. Thus, this study shows that VPA can be dosed to selectively manipulate the fibrinolytic system in the vascular compartment and reduce thrombus formation in vivo.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  HDAC inhibitor; fibrinolysis; thrombosis; tissue-type plasminogen activator; valproic acid

Mesh:

Substances:

Year:  2016        PMID: 27706906     DOI: 10.1111/jth.13527

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

Review 1.  Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.

Authors:  Martina Korfei; Poornima Mahavadi; Andreas Guenther
Journal:  Cells       Date:  2022-05-12       Impact factor: 7.666

2.  Valproic Acid Decreases Endothelial Colony Forming Cells Differentiation and Induces Endothelial-to-Mesenchymal Transition-like Process.

Authors:  Nathalie Nevo; Severine Lecourt; Ivan Bièche; Magda Kucia; Audrey Cras; Adeline Blandinieres; Sophie Vacher; Nicolas Gendron; Coralie L Guerin; Mariusz Z Ratajczak; David M Smadja
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

Review 3.  Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury.

Authors:  Zachary Pickell; Aaron M Williams; Hasan B Alam; Cindy H Hsu
Journal:  J Am Heart Assoc       Date:  2020-05-22       Impact factor: 5.501

4.  Dual mechanisms for the regulation of brain-derived neurotrophic factor by valproic acid in neural progenitor cells.

Authors:  Hyun Myung Ko; Yeonsun Jin; Hyun Ho Park; Jong Hyuk Lee; Seung Hyo Jung; So Young Choi; Sung Hoon Lee; Chan Young Shin
Journal:  Korean J Physiol Pharmacol       Date:  2018-10-25       Impact factor: 2.016

5.  HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice.

Authors:  Beatrix Scholz; Jan Sebastian Schulte; Sabine Hamer; Kirsten Himmler; Florentina Pluteanu; Matthias Dodo Seidl; Juliane Stein; Eva Wardelmann; Elke Hammer; Uwe Völker; Frank Ulrich Müller
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-03

Review 6.  Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells.

Authors:  George Anderson; Moses Rodriguez; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

7.  [Valproic Acid Could Help in the Fight Against COVID-19: a case-control study].

Authors:  Oscar Moreno-Pérez; Esperanza Merino; Jose Manuel Ramos; Juan Carlos Rodríguez; Carmina Diaz; Patricio Mas; Sergio Reus; Rosario Sánchez-Martínez; Vicente Boix; Pablo Chico-Sánchez; José Sánchez-Payá; Joaquín Portilla
Journal:  Neurologia       Date:  2022-02-14       Impact factor: 3.109

Review 8.  Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation.

Authors:  Marion Pilard; Estelle L Ollivier; Virginie Gourdou-Latyszenok; Francis Couturaud; Catherine A Lemarié
Journal:  Front Cardiovasc Med       Date:  2022-04-21

9.  Knowledge Graph-Based Approaches to Drug Repurposing for COVID-19.

Authors:  Jacob Al-Saleem; Roger Granet; Srinivasan Ramakrishnan; Natalie A Ciancetta; Catherine Saveson; Chris Gessner; Qiongqiong Zhou
Journal:  J Chem Inf Model       Date:  2021-07-23       Impact factor: 4.956

10.  Scanning laser-induced endothelial injury: a standardized and reproducible thrombosis model for intravital microscopy.

Authors:  P Larsson; V Tarlac; T-Y Wang; T Bonnard; C E Hagemeyer; J R Hamilton; R L Medcalf; S H Cody; N Boknäs
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.